Company Profiles

driven by the PitchBook Platform

OptiNose

OptiNose
2000 FOUNDED
PUBLIC STATUS
11-50 EMPLOYEES
IPO LATEST DEAL TYPE
$120M LATEST DEAL AMOUNT
$284M TOTAL AMOUNT RAISED
Description

Developer of exhalation delivery systems designed to improve quality of life for patients by providing better alternatives to existing treatments. The company's platform uses Exhalation Delivery Systems (EDS) capable of high and deep intranasal deposition of medication, enabling creation of products with the potential for meaningful new clinical benefits.

Website:
Ownership Status
Publicly Held
Financing Status
Formerly VC-Backed
Primary Industry
Drug Delivery
Other Industries
Other Devices and Supplies
Biotechnology
Primary Office
1020 Stony Hill Road
Third Floor, Suite 300
Yardley, PA 19067
United States

+1 (267) 364-3500
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore OptiNose’s full profile, request a free trial.

OptiNose Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. IPO 13-Oct-2017 $120M $284M 00000 Completed Clinical Trials - General
5. Later Stage VC (Series D) 07-Apr-2017 0000 00000 00000 Completed Clinical Trials - General
4. Merger/Acquisition 31-Oct-2015 00.000 00.000 Cancelled Clinical Trials - General
3. Grant 01-Feb-2016 00.00 00000 Completed Clinical Trials - General
2. Later Stage VC (Series C) 13-Oct-2015 $106M $127M $176M Completed Clinical Trials - General
1. Later Stage VC 18-Jun-2010 $21.1M $21.1M $71.1M Completed Startup
To view this company’s complete deal history including valuation and funding request access »

OptiNose Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series D 0,000,000 00.000000 000.00 000.00 00 000.00 0.000
Series C2 000,000 00.000000 000.0 000.0 00 000.0 0.000
Series C1 0,000,000 00.000000 000.00 000.00 00 000.00 00.000
Series C 0,000,000 00.000000 000.0 000.0 00 000.0 00.000
Series B2 000,000 00.000000 000.00 000.00 00 000.00 0.000
Series B1 35,680 $0.001000 $18.85 $18.85 1x $18.85 0.28%
Series A 285,480 $0.001000 $18.85 $18.85 1x $18.85 2.28%
To view this company’s complete Cap Table request access »

OptiNose Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Avista Capital Partners PE/Buyout Minority 000 0000 000000 0

OptiNose Executive Team (16)

Name Title Board
Seat
Contact
Info
Helena Djupesland Co-Founder and Co-Chief Executive Officer of OptiNose AS (Norway)
Peter Miller Chief Executive Officer & Board Member
Ramy Mahmoud MD President & Chief Operating Officer
Keith Goldan Chief Financial Officer
Tammy Mccauley Chief Administrative Officer
You’re viewing 5 of 16 executives. Get the full list »

OptiNose Board Members (10)

Name Representing Role Since Contact
Info
Jackson Phillips Avista Capital Partners Board Member 000 0000
Joshua Tamaroff Avista Capital Partners Board Member 000 0000
Klaas de Boer Entrepreneurs Fund Board Member 000 0000
Larry Pickering OptiNose Board Member 000 0000
Patrick O'Neill Ph.D Avista Capital Partners Board Member 000 0000

1 Former Board Members

You’re viewing 5 of 10 board members. Get the full list »